blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3853230

EP3853230 - CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  25.06.2021
Database last updated on 19.10.2024
FormerThe international publication has been made
Status updated on  28.03.2020
Most recent event   Tooltip17.08.2024New entry: Application deemed to be withdrawn: despatch of communication + time limit 
Applicant(s)For all designated states
Vyera Pharmaceuticals, LLC
600 Third Avenue, 10th Floor
New York, NY 10016 / US
For all designated states
Washington University
One Brookings Drive
St. Louis, Missouri 63130 / US
[2021/30]
Inventor(s)01 / HOPPER, Allen T.
75 Adams Street
Lexington, MA 02420 / US
02 / SIBLEY, L. David
7333 Teasdale Avenue
University City, MO 63130 / US
03 / JANETKA, James W.
7470 Teasdale Drive
St. Louis, MO 63130 / US
 [2021/30]
Representative(s)(deleted)
[N/P]
Former [2021/30]HGF
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date19863891.819.09.2019
[2021/30]
WO2019US51877
Priority number, dateUS201862733361P19.09.2018         Original published format: US 201862733361 P
[2021/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020061279
Date:26.03.2020
Language:EN
[2020/13]
Type: A1 Application with search report 
No.:EP3853230
Date:28.07.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 26.03.2020 takes the place of the publication of the European patent application.
[2021/30]
Search report(s)International search report - published on:IL26.03.2020
(Supplementary) European search report - dispatched on:EP03.06.2022
ClassificationIPC:C07D487/04, A61K31/519, A61P33/02, A61P33/06
[2021/30]
CPC:
C07D487/04 (EP,US); A61P33/02 (EP); A61P33/06 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/30]
Extension statesBA13.04.2021
ME13.04.2021
Validation statesKH13.04.2021
MA13.04.2021
MD13.04.2021
TN13.04.2021
TitleGerman:CDPK1-INHIBITOREN, ZUSAMMENSETZUNGEN UND VERFAHREN IM ZUSAMMENHANG DAMIT[2021/30]
English:CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO[2021/30]
French:INHIBITEURS DE CDPK1, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS[2021/30]
Entry into regional phase13.04.2021National basic fee paid 
13.04.2021Search fee paid 
13.04.2021Designation fee(s) paid 
13.04.2021Examination fee paid 
Examination procedure13.04.2021Examination requested  [2021/30]
29.12.2022Amendment by applicant (claims and/or description)
16.08.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
Fees paidRenewal fee
30.11.2021Renewal fee patent year 03
16.08.2022Renewal fee patent year 04
26.09.2023Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
30.09.202103   M06   Fee paid on   30.11.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search   [ ] - No further relevant documents disclosed
International search[X]WO2009062118  (FOLDRX PHARMACEUTICALS INC [US], et al) [X] 1-10, 12, 13, 16-21, 25-27, 35, 37, 39-41, 69, 70, 75 * Compounds 11, 19-22, 48, 50-52, 56, 58-60, 64, 65, 68, 90, 128, 133, 134, 137, 140, 142-147, 150, 165-169, 174-180, 183-185, 193-197, 200, 201, 205, 206, 220, 221, 256, 260, 278, 331, 341, 357-359, 362, 370, 380, 381, 386, 414, 417, 420, 429-432, 437, 438, 440, 441, 447-450, 454 and 463. *;
 [X]US2012077827  (IBRAHIM PRABHA N [US], et al) [X] 1-3, 5-10, 12, 13, 16, 37, 39-41, 69, 70, 75 * Compounds la-lc, 2a-2d, 4a-4d and paragraph [0090]. *;
 [X]WO2017161344  (THE REGANTS OF THE UNIV OF CALIFORNIA [US], et al) [X] 1-79 * The whole document. *;
 [XP]WO2018170236  (VYERA PHARMACEUTICALS LLC [US]) [XP] 1-16, 33-45, 57, 58, 61-79 * The whole document. *;
 [XP]WO2019036001  (VYERA PHARMACEUTICALS LLC [US], et al) [XP] 1-16, 33-45, 57, 58, 61-79* The whole document. *;
 [X]  - RUTAGANIRA, F. U. et al., "Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii", Journal of medicinal chemistry, vol. 60, no. 24, doi:10.1021/acs.jmedchem.7b01192, (20170921), pages 9976 - 9989, URL: https://europepmc.org/article/PMC/5746462, XP055571647 [X] 1-3, 5-10, 12, 13, 19-21, 23, 25-30, 35, 39, 40, 63-79 * Figures 1-3. *

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.7b01192
 [X]  - LOURIDO S. et al., "Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii", Journal of medicinal chemistry, vol. 56, no. 7, doi:10.1021/jm4001314, (20130326), pages 3068 - 3077, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625458, XP055479238 [X] 1, 2, 5-10, 12, 13, 19-21, 35, 39, 40, 63-79 * Figure 1 and Table 1. *

DOI:   http://dx.doi.org/10.1021/jm4001314
 [XY]  - KUHLENSCHMIDT, T. B. et al., "Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture", Antimicrob Agents Chemother, (20151109), vol. 60, no. 1, pages 570 - 579, XP055695132 [X] 1, 2, 4-8, 10, 12, 13, 19-21, 39, 40, 63-79 * Figure 1, compounds 9-20. Figure 1, compound 5. * [Y] 16, 36-38, 45, 61

DOI:   http://dx.doi.org/10.1128/AAC.01915-15
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.